Status:
RECRUITING
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
Lead Sponsor:
Amgen
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this study is to characterize the safety profile of sotorasib.
Eligibility Criteria
Inclusion
- Adult (≥ 18 years) as of the index date.
- KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
- Received at least 1 dose of sotorasib.
- Receipt of at least 1 prior systemic therapy before use of sotorasib.
- Obtained ICF, if required.
Exclusion
- Documentation of being a non-Chinese ethnicity.
Key Trial Info
Start Date :
August 11 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT07143513
Start Date
August 11 2025
End Date
June 30 2026
Last Update
September 12 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Boao Evergrande International Hospital
Qionghai, Hainan, China, 571400
2
Boao Super Hospital
Qionghai, Hainan, China, 571499
3
Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine Hainan Boao Research Hospital
Qionghai, Hainan, China, 57400